Zoloft is approved by the FDA to treat adults with Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), and Social Anxiety Disorder in adults.
Zoloft is in the Pregnancy category C.
Exposure during late pregnancy to SSRIs may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1-2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality.
In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy.
Women who are pregnant, plan to become pregnant, or who are breastfeeding should not take any antidepressant without consulting their doctor.
When treating a pregnant woman with Zoloft during the third trimester, the physician should carefully consider both the potential risks and benefits of treatment. Women who discontinued antidepressants during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication.
Is the antidepressant drug Zoloft responsible for your baby’s PPHN? Let’s connect the legal dots…